ImmunityBio touts preclinical data on NK cell therapy boosting product ImmunityBio has released preclinical data demonstrating that its lead cytokine infusion protein, Anktiva, an interleukin-15 "superagonist," improves interferon-gamma production and killing of tumor cells in vitro and in vivo by CD34+ progenitor-derived natural killer (NK) cells.
Regulatory Roundup: Gene therapies, bispecific antibodies lead new approvals Welcome to Regulatory Roundup, a new Science Advisory Board feature that tracks recent regulatory activities in the life sciences industry. Recent approvals over the past week have included an orphan drug designation for a new gene therapy, as well as approvals for a quadrivalent flu vaccine and a hepatitis B vaccine.
Immunomic, Colmmune partner on cancer immunotherapy Immunomic Therapeutics and CoImmune Therapeutics have entered into a license agreement for Immunomic to use CoImmune's proprietary dendritic cell process for certain Immunomic cell therapy vaccine programs.
Prevail Therapeutics granted gene therapy patent The U.S. Patent and Trademark Office has issued a composition of matter patent (No. 10,837,028) to Prevail Therapeutics for its adeno-associated viral vector used in PR001, an experimental gene therapy program for the treatment of Parkinson's disease with mutations in the BGA1 gene and neuropathic Gaucher disease.
Cue Biopharma, Merck expand Immuno-STAT collaboration Cue Biopharma has extended the terms of its research collaboration and license agreement with Merck toward developing new clinical candidates for the treatment of type 1 diabetes and an additional undisclosed autoimmune disease. The research will focus on in vivo Immuno-selective targeting and alteration of T cell (STAT) biologics that are designed for targeted modulation of disease-associated T cells in immune-oncology and autoimmune diseases.
AbCellera acquires Trianni for $90M Artificial intelligence-powered biotech and drug discovery platform AbCellera has purchased Trianni for $90 million. The deal boosts AbCellera's ability to create large human antibody databases for drug discovery.